People
Neos Therapeutics, Inc. announced the appointment of James Robinson to its board of directors.
Immunicum AB announced the composition of the Nomination Committee on 19 October 2018.
Lonza announced that Richard Ridinger, CEO, has decided to retire from the company after seven successful years.
Novartis Chief Executive Officer Vas Narasimhan said 2018 was a year of reimagining for Switzerland-based Novartis. It was a year when the company focused its capital and resourced on developing breakthrough medicines.
Singapore-based ASLAN slashed 30 percent of its staff following a recent mid-stage failure, and California-based Aduro has cut 37 percent of employees.
For 2018, Pfizer reported revenues of $53.6 billion, which was 2 percent operational growth. The fourth quarter brought in $14 billion, which was 5 percent operational growth.
As the trial against John Kapoor and other former executives at Insys Therapeutics continues, more sordid details of an aggressive campaign to boost sales of the company’s fentanyl-based sublingual spray for cancer pain are being brought to light.
Rentschler Biopharma SE appoints Dr. Christian Hunzinger as Senior Vice President Project Management
Rentschler Biopharma SE announced the appointment of Dr. Christian Hunzinger (48) as the new Senior Vice President Project Management, effective from January 15, 2019.
Robert Jacks, co-founder and former chief financial officer of Symbiomix Therapeutics, has taken over the reins of Cambridge, Mass.-based Indalo Therapeutics and will help guide the company in the development of therapies for patients suffering from serious fibrotic diseases such as NASH and idiopathic pulmonary fibrosis (IPF).
The U.S. Senate Finance Committee and the House Oversight Committee started hearings on Tuesday, January 29, focused on dealing with high drug prices.
PRESS RELEASES